维普中文期刊产品整合服务
22篇 您的检索式:作者名="Ravinder B"
    题名 作者 年代 出处 被引量
1Relatival biological effectiveness of 103Pd and 125I photons for continuous low dose rate irradiation of Chinese hamster cells显示文摘Ravinder N Paul B Zhe C 0,,05:1
2Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection显示文摘Paul M Beer Sophie J Bakri Ravinder J Singh Weiguo Liu George B Peters Michael Miller 2003Ophthalmology2003,,4:1
3Synthesis, photochemical E (trans)/Z (cis)isomerization and antimicrobial activity of 2-chloro-5 -methylpyridine -3 -olefin derivatives 显示文摘Gangadasu B Janaki M R R Ravinder M 2009European Joumal of Medicinal Chemistry2009,44,:1
4Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection显示文摘Paul M Beer Sophie J Bakri Ravinder J Singh Weiguo Liu George B Peters Michael Miller 2003Ophthalmology2003,,4:1
5Fermentative production of acetic from various pure and natural cellulosic materials by Clostridium lentocellum SG6显示文摘Ravinder T Ramesh B Seenayya G 2000World Journal of Microbiology & Biotechnology2000,16,50:1
6Electrical conductivity of cerium substituted Mn-Zn ferrites 显示文摘Ravinder D Kumar B R 2003Materials Letters2003,57,:1
7The role of glutathine in the transport and catabolism of nitric oxide 显示文摘 Ravinder J Singh B 1996FEBS Lett1996,382,3:1
8Effect of Deterministic Asperity Geometry on HydrodynamicLubrication显示文摘Ravinder B Siripuram Lyndon S Stephens 2004ASME Journal of Tribology2004,126,7:1
9显示文摘Ravinder D Kumar B R 2003Mater Lett2003,57,:1
10Design of helix slow-wave structures for high efficiency TWTs显示文摘Srivastava V Cater R G Ravinder B 2000IEEE Trans on Electron Devices2000,47,6:1
11Accurate Reporting of Door-to- Balloon Times 显示文摘Jerome MG Atifur R Ravinder B 2015Heart lung & circulation2015,24,12:1
12Design of Helix Slow-Wave Structures for High Efficiency TWTS 显示文摘Srivastava V Carter R C Ravinder B 2000IEEE Trans on Electron Devices2000,47,12:1
13Ex- traction, Identification, Formulation and evalution of pip- ertine in alginate beads显示文摘BINDU M B RAVINDER N A DAVID B 2009International Journal of Pharmacy and Pharmacentical Sciences2009,1,2:1
14Design ol helix slow-wave structures for high efficiency TWTs显示文摘Srivastava V Carter R G Ravinder B 2000IEEE Trans on Electron Devices2000,47,12:1
15Thermal Characteristics of a Classical Solar Telescope Primary Mirror显示文摘Ravinder K Banyal Ravindra B Chatterjee S 0,,1384:1
16IEEE Trans Electron Devices 显示文摘Srivastava V Carter R G Ravinder B 200047 ( 12 ) : 2438 - 24432000,47,12:1
17An efficient synthesis for eslicarbazepine acetate, oxcarbazepine and carbamazepine 显示文摘RAVINDER B RAJESHWAR R S SRIDHA M 2013Tetrahedron Lett2013,54,22:1
18Chronic atrial fibrillation in patients with rheumatic heart disease:mapping and radiofrequency ablation of flutter circuits seen at initiation after cardioversion 显示文摘Mohan N Prasad S Ravinder B 2001Circulation2001,104,:1
19Design of Helix Slow-Wave Structures for High Efficiency TWTs显示文摘Vishnu Srivastava Carter R G Ravinder B etal 2000IEEE Trans on Electron Devices2000,47,12:1
20Systematic overview of hepatitis C infection in the Middle East and North Africa显示文摘AIM To assess the quality of and to critically synthesize the available data on hepatitis C infections in the Middle East and North Africa(MENA) region to map evidence gaps.METHODS We conducted an overview of systematic reviews(SRs) following an a priori developed protocol(CRD42017076736). Our overview followed the preferred reporting items for systematic reviews and metaanalyses guidelines for reporting SRs and abstracts and did not receive any funding. Two independent reviewers systematically searched MEDLINE and conducted a multistage screening of the identified articles. Out of 5758 identified articles, 37 SRs of hepatitis C virus(HCV) infection in populations living in 20 countries in the MENA region published between 2008 and 2016 were included in our overview. The nine primary outcomes of interest were HCV antibody(anti-) prevalences and incidences in different at-risk populations; the HCV viremic(RNA positive) rate in HCV-positive individuals; HCV viremic prevalence in the general population(GP); the prevalence of HCV co-infection with the hepatitis B virus, human immunodeficiency virus, or schistosomiasis; the HCV genotype/subtype distribution; and the risk factors for HCV transmission. The conflicts of interest declared by the authors of the SRs were also extracted. Good quality outcomes reported by the SRs were defined as having the population, outcome, study time and setting defined as recommended by the PICOTS framework and a sample size > 100.RESULTS We included SRs reporting HCV outcomes with different levels of quality and precision. A substantial proportion of them synthesized data from mixed populations at differing levels of risk for acquiring HCV or at different HCV infection stages(recent and prior HCV transmissions). They also synthesized the data over long periods of time(e.g., two decades). Anti-HCV prevalence in the GP varied widely in the MENA region from 0.1%(study dates not reported) in the United Arab Emirates to 2.1%-13.5%(2003-2006) in Pakistan and 14.7%(2008) in Egypt. Data were not identified for Bahrain, Jordan, or Palestine. Good quality estimates of anti-HCV prevalence in the GP were reported for Algeria, Djibouti, Egypt, Iraq, Morocco, Pakistan, Syria, Sudan, Tunisia, and Yemen. Anti-HCV incidence estimates in the GP were reported only for Egypt(0.8-6.8 per 1000 person-year, 1997-2003). In Egypt, Morocco, and the United Arab Emirates, viremic rates in anti-HCV-positive individuals from the GP were approximately 70%. In the GP, the viremic prevalence varied from 0.7%(2011) in Saudi Arabia to 5.8%(2007-2008) in Pakistan and 10.0%(2008) in Egypt. Anti-HCV prevalence was lower in blood donors than in the GP, ranging from 0.2%(1992-1993) in Algeria to 1.7%(2005) in Yemen. The reporting quality of the outcomes in blood donors was good in the MENA countries, except in Qatar where no time framework was reported for the outcome. Some countries had anti-HCV prevalence estimates for children, transfused patients, contacts of HCV-infected patients, prisoners, sex workers, and men who have sex with men.CONCLUSION A substantial proportion of the reported outcomes may not help policymakers to develop micro-elimination strategies with precise HCV infection prevention and treatment programs in the region, as nowcasting HCV epidemiology using these data is potentially difficult. In addition to providing accurate information on HCV epidemiology, outcomes should also demonstrate practical and clinical significance and relevance. Based on the available data, most countries in the region have low to moderate anti-HCV prevalence. To achieve HCV elimination by 2030, up-to-date, good quality data on HCV epidemiology are required for the GP and key populations such as people who inject drugs and men who have sex with men.Karima Chaabna Sohaila Cheema Amit Abraham Hekmat Alrouh Albert B Lowenfels Patrick Maisonneuve Ravinder Mamtani 2018World Journal of Gastroenterology2018,24,27:1
返回顶部 每页显示:
共2页 首页 上一页 第1页 下一页 末页 /2 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费